Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 

Telehealth-Delivered Opioid Agonist Therapy for the Treatment of Adults with Opioid Use Disorder: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

This Rapid Response report aims to review the effectiveness of the use of telehealth-delivered OAT compared to standard OAT.
Lit review | 2018
Clinical guidance, Evidence base, Policy/Regulatory, Safer supply, About prescribers

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report

Users of poppy seed tea (PST) can consume several hundred morphine milligram equivalents per day, and opioid dependence from PST use can develop.
Original research | 2021
Withdrawal, Clinical guidance, Hesitancy of prescribers , About prescribers, Outcomes, Chronic pain, Substitution/OAT, Stigma

Safer Opioid Supply Programs (SOS): A Harm Reduction Informed Guiding Document for Primary Care Teams

Despite a current lack of direct evidence, this document has been created to urgently combat overdose deaths. It is informed by existing research and based out of expert opinion.
Guidelines | 2020
Mortality, Clinical guidance, Harm reduction, Safer supply, About prescribers, Transitions in care/treatment, Injecting drugs, Diversion

Substance Replacement Therapy in the Context of the COVID-19 Pandemic in Québec: Clinical Guidance for Prescribers

Quebec safe supply clinical guidance for prescribers
Guidelines | 2020
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs

An introductory guide for assessing and understanding common wounds with people who inject drugs

Guide or handbook | 2020
Clinical guidance, Harm reduction, Illegal drugs, Injecting drugs

The Structure, Growth, and Development of an Addiction Medicine & Rural Service

Slide deck | 2021
Clinical guidance, About prescribers, Small/medium cities

Bioequivalence Following Buccal and Sublingual Placement of Fentanyl Buccal Tablet 400μg in Healthy Subjects

FBT is indicated for the management of breakthrough pain (a transient flare of pain on a background of chronic pain otherwise controlled by treatment with opioids) in patients with cancer who are alre
Original research | 2008
Clinical guidance, About prescribers, Chronic pain

Clinical Management of Cannabis Withdrawal

This review describes the diagnosis, prevalence, course and management of cannabis withdrawal and highlights opportunities for future clinical research.
Lit review | 2021
Withdrawal, Clinical guidance

Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl Pharmacokinetics

Assess whether 4x100μg fentanyl buccal tablets had the same biological effect as 1 400μg tablet
Original research | 2006
Clinical guidance, About prescribers

Hospital Buprenorphine Program for Opioid Use Disorder Is Associated With Increased Inpatient and Outpatient Addiction Treatment

This study reports the outcomes of the B-Team (Buprenorphine-Team), a hospitalist-led interprofessional program created to identify hospitalized patients with OUD, initiate buprenorphine in the inpati
Original research | 2021
Clinical guidance, Evidence base, Wrap-around services, About prescribers, Outcomes, Substitution/OAT, Transitions in care/treatment, Hospitals

Caring for hospital patients who inject drugs

Slide deck | 2019
Clinical guidance, Harm reduction, About prescribers, Illegal drugs, Hospitals

Caring for people who inject drugs when they are admitted to hospital

Commentary | 2021
Withdrawal, Clinical guidance, Policy/Regulatory, About prescribers, Illegal drugs, Stigma, Hospitals

National Injectable Opioid Agonist Treatment Guideline

The clinical guideline was developed to provide key clinical recommendations, as well as clinical guidance on the provision of iOAT.
Guidelines | 2019
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Illegal drugs, Stimulants, Transitions in care/treatment, Injecting drugs

BCCSU Webinars

Archived webinar | various
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Injecting drugs

BCCSU Webinars: COVID-19, Substance Use, and Safer Supply

Archived webinar | 2020
Clinical guidance, Harm reduction, Safer supply, About pharmacists, About prescribers, Housing

Fentanyl Buccal Tablet In Breakthrough Pain in Opioid-Tolerant Patients with Cancer

Report | 2006
Clinical guidance, Chronic pain

Guidance for Injectable Opiod Agonist Treatment for Opioid Use Disorder

Guidelines | 2017
Clinical guidance, Evidence base, Policy/Regulatory, About prescribers

Guideline for the Clinical Management of Opioid Use Disorder

Guidelines | 2023
Clinical guidance, Policy/Regulatory, About prescribers

Implementing social interventions in primary care

We discuss accumulated evidence (Box 1) on social interventions and provide an overview of common primary care–based interventions (Table 1), highlighting their strengths, limitations and feasibility
Lit review | 2021
Clinical guidance, Wrap-around services, Equity, About prescribers, Social services

Risk Mitigation in the Context of Dual Public Health Emergencies

BC safe suply interim guidance for safe supply/COVID-19 risk mitigation during the pandemic

Guidelines | 2022
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Rural/remote, Substitution/OAT, Carries/take-home doses

Affiner votre recherche

Mots clés
Format
Région